Oxford Biomedica - COVID vaccine and Kymriah news encouraging
Oxford Biomedica (OXB) announced that it has signed a new three-year Master Services and Development Agreement with AstraZeneca (AZN) for future...
673 Views
Global Equity Strategy: Opportunities In Real Estate and Health Care
The weight of the evidence continues to support our mixed, but overall constructive outlook. We outline the basis for our outlook and also...
181 Views
Oxford Biomedica - Driving innovation in a thriving CGT industry
Oxford Biomedica (OXB) is one of few global lentiviral vector manufacturers with capacity in a thriving cell and gene therapy industry, and its...
566 Views
Video: Oxford Biomedica – executive interview
Why are investors buying into Oxford Biomedica (LN:OXB)? In this interview, BBC broadcaster Vivienne Parry OBE asks CEO John Dawson why Oxford...
617 Views
Oxford Biomedica - Vector innovation key to cell and gene evolution
Oxford Biomedica (OXB) is a pioneer and global leader in the development and manufacture of commercial-scale lentiviral vectors (LVVs), a critical...
245 Views